accès aux médicaments

Oxfam has hailed the Indian Supreme Court’s ruling against a patent protection petition filed by multinational pharmaceutical company Novartis as a huge victory for public health.

 

 

Pharmaceutical giant Novartis is back in court this week, in a renewed attempt to block India’s right to produce affordable ‘generic’ versions of the company’s branded medicines.

Oxfam strongly welcomes the European Parliament’s vote against the Anti-Counterfeiting Trade Agreement (ACTA) by a majority of 478 votes out of 682. ACTA would have posed a serious

On the eve of a high-level summit between the leaders of India and the European Union in Delhi, Oxfam is calling on the EU not to pressure India into agreeing new trade rules that could deny hundreds of millions of people access to affordable medicines.

New Oxfam report: The proliferation of substandard medicines in poor countries is being used by rich countries as an excuse to tighten intellectual property rules, boosting the profits of large pharmaceutical companies while making it harder for poor people to get access to the medicines they need.

Poor-quality, or “substandard”, medicines threaten patients and public health in developing countries.

World leaders made no real commitments to ensure universal access to prevention, treatment and care for AIDS at this week's International AIDS conference in Vienna.